[ClH:1].Cl.[Br:3][C:4]1[CH:5]=[C:6]([CH:37]=[C:38]([C:40]([F:43])([F:42])[F:41])[CH:39]=1)[C:7]([N:9]([CH2:11][C@H:12]([C:30]1[CH:35]=[CH:34][C:33]([F:36])=[CH:32][CH:31]=1)[CH2:13][CH2:14][N:15]1[CH2:18][CH:17]([N:19]2[CH2:24][CH2:23][N:22]3[C:25](=[O:29])[CH2:26][CH2:27]C[CH:21]3[CH2:20]2)[CH2:16]1)[CH3:10])=[O:8].N1CC(N2CCN(C(=O)CC)CC2)C1.C(O[BH-](OC(=O)C)OC(=O)C)(=O)C.[Na+].CCN(C(C)C)C(C)C>C(Cl)Cl.CO>[ClH:1].[ClH:1].[Br:3][C:4]1[CH:5]=[C:6]([CH:37]=[C:38]([C:40]([F:41])([F:42])[F:43])[CH:39]=1)[C:7]([N:9]([CH2:11][C@H:12]([C:30]1[CH:35]=[CH:34][C:33]([F:36])=[CH:32][CH:31]=1)[CH2:13][CH2:14][N:15]1[CH2:18][CH:17]([N:19]2[CH2:20][CH2:21][N:22]([C:25](=[O:29])[CH2:26][CH3:27])[CH2:23][CH2:24]2)[CH2:16]1)[CH3:10])=[O:8]3-Bromo-N-[(2S)-2-(4-fluorophenyl)-4-oxobutyl]-N-methyl-5-(trifluoromethyl)benzamide (see Method 3; 165 mg, 0.4 mmol) and 1-azetidin-3-yl-4-propionylpiperazine (see Method 7; 80 mg, 0.41 mmol) were dissolved in methylene chloride (10 mL) together with a small amount of dry methanol (0.2 mL). Sodium triacetoxyborohydride (157 mg, 0.74 mmol) was added together with DIPEA (143 mg, 1.11 mmol). The reaction mixture was stirred at RT for 2.5 h and then diluted with methylene chloride. The solution was washed twice with aqueous NaHCO3 and then with brine. The organic phase was separated by means of a phase separator column and then the solvent was removed by evaporation. The product was purified by chromatography on silica gel (methanol-methylene chloride 5:95). The oily product was dissolved in 2M hydrochloric acid and the solvent was then removed by freeze-drying. There was obtained 120 mg (48%) of the title compound as a white solid. 1H NMR (500 MHz, CDCl3): 1.2-3.8 (cm, 28H), 6.8-7.8 (cm, 7H); LCMS: m/z 628 (M+1)+.
読み込み中…